Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25640010 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL7263734 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL436333 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL26032485 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL12238318 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL25257785 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL14671684 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL12092148 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL22939187 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL25639770 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705299-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | Rayzebio, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | PRELUDE THERAPEUTICS INCORPORATED | 2025-09-04 | — | — | US | disclosed |
| WO-2025105486-A1 | ANTIBODY-PHOTOSENSITIVE SUBSTANCE CONJUGATE | 第一三共株式会社 | 2025-05-22 | — | — | WO | disclosed |
| US-20250144224-A1 | ABL INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-05-08 | — | — | US | disclosed |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-04-03 | — | — | US | disclosed |
| US-20250092111-A1 | POTENT AND STABLE POLYPEPTIDE ANALOGUES VIA SERINE/THREONINE LIGATION | UNIVERSITY OF WASHINGTON | 2025-03-20 | — | — | US | disclosed |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240408247-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-12-12 | — | — | US | disclosed |
| EP-4463464-A2 | POTENT AND STABLE POLYPEPTIDE ANALOGUES VIA SERINE/THREONINE LIGATION | University of Washington (US) | 2024-11-20 | — | — | EP | disclosed |
| US-10980889-B1 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3788050-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3788049-A1 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3787691-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | Tagworks Pharmaceuticals B.V. (NL) | 2021-03-10 | — | — | EP | disclosed |
| EP-3788032-A1 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | Tagworks Pharmaceuticals B.V. (NL) | 2021-03-10 | — | — | EP | disclosed |
| WO-2020201743-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LIMITED (GB) | 2020-10-08 | — | — | WO | disclosed |
| US-20190336609-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | Revolution Medicines, Inc. | 2019-11-07 | — | — | US | disclosed |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-11-07 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980889-B1 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | MEN1 369/4885KMT2A 3334/4885GAA 1806/4885 |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | VIP, PTMS, PDGFA | MEN1 1142/4885KMT2A 4517/4885GAA 1909/4885 |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | MEN1 369/4885KMT2A 3334/4885GAA 1806/4885 |
| US-20240408247-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | GRPR, SCTR, NPSR1 | MEN1 1446/4885KMT2A 4330/4885GAA 2275/4885 |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | MEN1 744/4885KMT2A 2883/4885GAA 1115/4885 |
| US-20190336609-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | MEN1 369/4885KMT2A 3334/4885GAA 1806/4885 |
| US-20250144224-A1 | ABL INHIBITORS AND USES THEREOF | ABL1, ABL2, ALK | MEN1 2964/4885KMT2A 193/4885GAA 1441/4885 |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | MEN1 3278/4885KMT2A 3699/4885GAA 4198/4885 |
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | CRBN, RBX1, SMARCE1 | MEN1 1360/4885KMT2A 253/4885GAA 1096/4885 |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | RICTOR, MTOR, MLST8 | MEN1 380/4885KMT2A 1272/4885GAA 4223/4885 |
| US-20250092111-A1 | POTENT AND STABLE POLYPEPTIDE ANALOGUES VIA SERINE/THREONINE LIGATION | PTMS, DNPEP, TSSK6 | MEN1 629/4885KMT2A 1702/4885GAA 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.